Literature DB >> 8807045

Treatment of experimental endocarditis due to ampicillin-susceptible or ampicillin-resistant Salmonella enteritidis.

M L Fernández Guerrero1, R Torres Perea, C Verdejo Morcillo, R Fernández Roblas, M de Górgolas.   

Abstract

Using two strains of Salmonella enteritidis, one susceptible and one resistant to ampicillin, we studied the efficacies of ampicillin, gentamicin, ampicillin plus gentamicin, ofloxacin, and cefotaxime for the treatment of experimental salmonella endocarditis. Rabbits were treated for 3 days with dosages of antibiotic selected to achieve concentrations in serum equivalent to those obtained in humans during therapy. Aortic salmonella endocarditis seemed to be very difficult to treat, and all antimicrobial regimens failed to achieve the complete sterilization of cardiac vegetations. In vitro studies did not accurately predict the in vivo response to therapy, and no correlations regarding the synergistic activity of the combination of ampicillin plus gentamicin were observed. For the ampicillin-susceptible S. enteritidis isolate, ampicillin and cefotaxime produced the greatest reduction in the number of organisms in vegetations, with no significant differences between them. For the ampicillin-resistant strain, the combination of ampicillin with gentamicin produced a synergistic effect that was not anticipated by the in vitro studies. Both cefotaxime and ofloxacin were effective in reducing the number of microorganisms in the vegetations, although the reduction produced by cefotaxime was less that that produced against the ampicillin-susceptible strain. Monotherapy with gentamicin exhibited only modest activity against the ampicillin-susceptible S. enteritidis strain.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8807045      PMCID: PMC163378     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  Failure of kanamycin in the treatment of typhoid fever.

Authors:  H D RILEY; N J RYAN
Journal:  J Pediatr       Date:  1961-08       Impact factor: 4.406

2.  Septicemia with non-typhoid salmonella.

Authors:  C E Cherubin; H C Neu; P J Imperato; R P Harvey; N Bellen
Journal:  Medicine (Baltimore)       Date:  1974-09       Impact factor: 1.889

3.  Pharmacokinetics of ofloxacin after single and multiple intravenous infusions in healthy subjects.

Authors:  R Farinotti; J H Trouvin; V Bocquet; N Vermerie; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

4.  The risk of endothelial infection in adults with salmonella bacteremia.

Authors:  P S Cohen; T F O'Brien; S C Schoenbaum; A A Medeiros
Journal:  Ann Intern Med       Date:  1978-12       Impact factor: 25.391

5.  Case-control study of infections with Salmonella enteritidis phage type 4 in England.

Authors:  J M Cowden; D Lynch; C A Joseph; M O'Mahony; S L Mawer; B Rowe; C L Bartlett
Journal:  BMJ       Date:  1989-09-23

Review 6.  Problems in salmonellosis: rationale for clinical trials with newer beta-lactam agents and quinolones.

Authors:  J P Bryan; H Rocha; W M Scheld
Journal:  Rev Infect Dis       Date:  1986 Mar-Apr

7.  Dose linearity testing of intravenous ofloxacin, a novel gyrase inhibitor.

Authors:  M Verho; A Korn; M Badian; V Malerczyk; W Waldhäusl
Journal:  Chemotherapy       Date:  1988       Impact factor: 2.544

8.  Cephalosporin therapy for salmonellosis. Questions of efficacy and cross resistance with ampicillin.

Authors:  C E Cherubin; R H Eng; S M Smith; E J Goldstein
Journal:  Arch Intern Med       Date:  1986-11

9.  Cefamandole treatment of Salmonella bacteremia.

Authors:  E M De Carvalho; R Martinelli; M M De Oliveira; H Rocha
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

10.  Comparative efficacies of ceftriaxone, moxalactam, and ampicillin in experimental Salmonella typhimurium infection.

Authors:  P A Anton; J A Kemp; T Butler; M R Jacobs
Journal:  Antimicrob Agents Chemother       Date:  1982-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.